UniQure pauses dosing in Fabry disease trial amid safety concerns
UniQure has ceased dosing in two cohorts in a Phase I/IIa trial of its adeno-associated viral (AAV) gene therapy, AMT-191,…
Latest News
-
-
Bayer’s Factor XIa inhibitor reduces repeat stroke risk by 26% in pivotal trial
Bayer’s investigational, once-daily, oral Factor XIa inhibitor asundexian reduced the risk of recurrent ischemic stroke by 26% in a pivotal…
-
Lilly stops development of three drugs, including gene therapy
Eli Lilly is dropping the development of three therapies that did not meet expectations, including a gene therapy acquired during…
-
NMD Pharma to progress CMT pill despite primary endpoint miss
NMD Pharma is “accelerating development” of its lead rare disease candidate, ignaseclant, in Charcot-Marie-Tooth (CMT), despite the drug failing to…
-
Pfizer’s acquired monthly weight loss drug meets endpoints in Phase IIb trial
Pfizer’s recently acquired weight loss injection has shown to maintain weight loss after a switch from weekly to monthly dosing…
-
Novo Nordisk’s CagriSema outperforms Ozempic in Phase III trial
Novo Nordisk’s CagriSema has outperformed the company’s flagship type 2 diabetes drug Ozempic (semaglutide) in both HbA1c levels and weight…
-
Oncology trial systems debut at SCOPE 2026 as AI adoption accelerates
Massive Bio and ConcertAI have each introduced artificial intelligence (AI)-based systems aimed at supporting oncology clinical trials at the Summit…
-
Biorce secures $52.5m in Series A to expand AI clinical trial tech
Spanish healthtech company Biorce has secured $52.5m through a Series A funding round to support the global rollout of its…
-
Sanofi records win and loss with rare disease drug in Phase III trials
Sanofi’s rare disease drug venglustat has met the primary endpoint in a Phase III trial in Gaucher disease but missed…
-
Quince Therapeutics’ stock crashes on Phase III ataxia-telangiectasia failure
Quince Therapeutics’ stock has fallen by more than 90% after a Phase III trial of its Ataxia-Telangiectasia (A-T) drug failed…
